Efficacy of halobetasol and tazarotene lotion for plaque psoriasis utilizing IGAxBSA measurements

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Green, Lawrence J. ^{[2
]}

Bagel, Jerry ^{[3
]}

Lin, Tina ^{[4
]}

Martin, Gina ^{[5
]}

Israel, Robert ^{[5
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA

[3] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA

[4] Ortho Dermatol, Bridgewater, NJ USA

[5] Bausch Hlth, Bridgewater, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

9785

引用

页码：AB201 / AB201

页数：1

共 50 条

[41] Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis
Weinstein, GD
BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 : 32 - 36
[42] A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis
Kerdel, Francisco A.
Draelos, Zoe D.
Tyring, Stephen K.
Lin, Tina
Pillai, Radhakrishnan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 333 - 339
[43] Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology
Tanghetti, Emil A.
Gold, Linda Stein
Del Rosso, James Q.
Lin, Tina
Angel, Arturo
Pillai, Radhakrishnan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (04) : 391 - 398
[44] A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis
Radonjic, Aleksandar
Evans, Emily L.
DERMATOLOGIC THERAPY, 2019, 32 (04)
[45] A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis
Sugarman, Jeffrey L.
Gold, Linda Stein
Lebwohl, Mark G.
Pariser, David M.
Alexander, Binu J.
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (03) : 197 - 204
[46] Clinical safety of tazarotene in the treatment of plaque psoriasis
Marks, R
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (02) : S25 - S32
[47] Topical halobetasol propionate in the treatment of plaque psoriasis - A review
Rivera, AM
Hsu, S
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2005, 6 (05) : 311 - 316
[48] Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)
Gold, Linda Stein
Lain, Edward
Bagel, Jerry
Jacobson, Abby
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB156 - AB156
[49] THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
Lozano-Ortega, G.
Rogula, B.
Gaudet, V
Mickle, A.
Johnston, K.
Barbeau, M.
VALUE IN HEALTH, 2019, 22 : S363 - S363
[50] Two multicenter, randomized, double-blind, parallel group comparison studies of halobetasol propionate lotion, 0.05% versus vehicle lotion in adult subjects with plaque psoriasis
Pariser, David
Bukhalo, Michael
Guenthner, Scott
Kempers, Steven
Shideler, Stephen
Gold, Linda Stein
Tschen, Eduardo
Berg, James
Ferdon, Mary Beth
Piacquadio, Daniel
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB280 - AB280

← 1 2 3 4 5 →